Press Releases Inhibrx, Inc.

Equities

INBX

US45720L1070

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
34.29 ^USD	-1.15%		+0.41%	-9.76%

09/05	Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
28/02	Inhibrx Shares Fall After Q4 Net Loss Widens	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off	04:07am	PR
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K	10/05	PU
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	10/05	BU
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger	09/05	PR
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX	27/03	PR
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results	28/02	PR
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	10/02	BU
Sanofi bets $1.7b on potential best-in-class rare disease therapy	24/01	AQ
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline	24/01	AQ
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi	23/01	PR
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders	23/01	BU
Mintz Launches Podcast Series On Women Leaders In Health Care	13/12	AQ
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma	02/11	PR
Inhibrx Announces Participation in Upcoming Scientific Conferences	19/23/19	PR
Inhibrx : Poster Presentation	17/23/17	PU
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada	20/23/20	AQ
Inhibrx Announces $200 Million Private Placement Financing	29/23/29	PR
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	08/23/08	PR
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency	30/23/30	PR
INHIBRX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	26/23/26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Inhibrx, Inc.

Equities

INBX

US45720L1070

Press Releases

Filters